共 50 条
Temporal bone management in external and middle ear carcinoma
被引:0
|作者:
Gowrishankar, Shravan
[1
]
Borsetto, Daniele
[1
,4
]
Marinelli, John
[2
]
Panizza, Ben
[3
]
机构:
[1] Cambridge Univ Hosp NHS Trust, Dept Otolaryngol Head & Neck Surg, Cambridge, England
[2] Dept Otolaryngol Head & Neck Surg, Mayo Clin, Rochester, MN USA
[3] Princess Alexandra Hosp, Dept Otolaryngol Head & Neck Surg, Brisbane, Qld, Australia
[4] Addenbrookes Hosp, Clin 10, Hills Rd, Cambridge CB2 0QQ, England
关键词:
immunotherapy;
neck dissection;
PD-1;
inhibitors;
petrosectomy;
squamous cell carcinoma;
temporal bone carcinoma;
temporal bone resection;
SQUAMOUS-CELL CARCINOMA;
CANCER;
SURVIVAL;
OUTCOMES;
D O I:
10.1097/MOO.0000000000000959
中图分类号:
R76 [耳鼻咽喉科学];
学科分类号:
100213 ;
摘要:
Purpose of reviewThe purpose of this review is to outline the temporal bone management of external and middle ear carcinoma. The review will outline the current evidence involved in deciding which surgical approach to take, as well as new advances in auditory rehabilitation and immunotherapy.Recent findingsTraditional surgical approaches include lateral temporal bone resection, subtotal temporal bone resection and total temporal bone resection. They can also involve parotidectomy and neck dissection depending on extension of disease into these areas. Options for auditory rehabilitation include osseointegrated hearing aids, transcutaneous bone-conduction implants, and active middle ear implants. Recent advances in immunotherapy have included the use of anti-PD-1 monoclonal antibodies.SummaryThe mainstay of management of temporal bone disease involves surgical resection. Early-stage tumours classified according to the Pittsburgh staging tool can often be treated with lateral temporal bone resection, whereas late-stage tumours might need subtotal or total temporal bone resection. Parotidectomy and neck dissection might also be indicated if there is a risk of occult regional disease. Recent advances in immunotherapy have been promising, particularly around anti-PD-1 inhibitors. However, larger clinical trials will be required to test the extent of efficacy, particularly around combination use with surgery.
引用
收藏
页码:138 / 142
页数:5
相关论文